Market Overview - The MASH (Metabolic Associated Steatotic Hepatitis) space is experiencing significant growth due to recent regulatory approvals of two drugs for treatment, addressing a substantial unmet medical need [2] - The approval of Rezdiffra last year and the recent approval of sema are expected to enhance market expansion and increase diagnosis rates among MASH patients [2] Patient Impact - There are millions of MASH patients, but a large majority remain undiagnosed and untreated, indicating a critical opportunity for market growth and patient care improvement [2]